9,984 Shares in Natera, Inc. (NASDAQ:NTRA) Acquired by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd bought a new stake in Natera, Inc. (NASDAQ:NTRA - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 9,984 shares of the medical research company's stock, valued at approximately $1,267,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. Cetera Investment Advisers grew its position in shares of Natera by 514.9% during the 1st quarter. Cetera Investment Advisers now owns 19,700 shares of the medical research company's stock worth $1,802,000 after purchasing an additional 16,496 shares in the last quarter. Cetera Advisors LLC acquired a new stake in Natera during the first quarter worth approximately $442,000. Wealth Enhancement Advisory Services LLC increased its stake in Natera by 59.6% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 9,218 shares of the medical research company's stock worth $998,000 after acquiring an additional 3,442 shares during the period. Envestnet Portfolio Solutions Inc. increased its stake in Natera by 50.6% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 13,622 shares of the medical research company's stock worth $1,475,000 after acquiring an additional 4,575 shares during the period. Finally, Swedbank AB acquired a new position in Natera in the 2nd quarter valued at $2,166,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Trading Down 0.4 %

Shares of NASDAQ:NTRA traded down $0.67 during midday trading on Thursday, hitting $166.45. 964,003 shares of the stock were exchanged, compared to its average volume of 1,330,884. The business's 50-day moving average price is $142.48 and its 200 day moving average price is $123.76. The stock has a market capitalization of $21.97 billion, a price-to-earnings ratio of -94.95 and a beta of 1.63. Natera, Inc. has a 12 month low of $57.22 and a 12 month high of $175.63. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39.

Natera (NASDAQ:NTRA - Get Free Report) last posted its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, topping analysts' consensus estimates of ($0.57) by $0.31. The firm had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company's revenue for the quarter was up 63.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.95) EPS. Analysts predict that Natera, Inc. will post -1.61 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on NTRA shares. Robert W. Baird raised their price target on Natera from $120.00 to $160.00 and gave the stock an "outperform" rating in a research report on Wednesday, November 13th. StockNews.com lowered shares of Natera from a "hold" rating to a "sell" rating in a report on Thursday, November 14th. Leerink Partners upped their price target on shares of Natera from $140.00 to $150.00 and gave the stock an "outperform" rating in a report on Thursday, October 17th. Canaccord Genuity Group lifted their price objective on shares of Natera from $150.00 to $165.00 and gave the company a "buy" rating in a research note on Wednesday, November 13th. Finally, The Goldman Sachs Group upped their target price on Natera from $125.00 to $140.00 and gave the stock a "buy" rating in a research note on Wednesday, October 16th. One equities research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $140.59.

Insider Activity at Natera

In other news, insider Jonathan Sheena sold 2,700 shares of the company's stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $127.57, for a total value of $344,439.00. Following the sale, the insider now directly owns 284,741 shares of the company's stock, valued at approximately $36,324,409.37. This represents a 0.94 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Roelof Botha sold 87,473 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $169.12, for a total transaction of $14,793,433.76. Following the sale, the director now owns 1,224,787 shares of the company's stock, valued at approximately $207,135,977.44. This trade represents a 6.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 140,601 shares of company stock worth $22,229,346 over the last three months. Company insiders own 7.60% of the company's stock.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.